Lynparza

Adult Dosing .

Dosage forms:  TAB: 100 mg, 150 mg

Restricted Distribution in US

[1-844-275-2360 or www.lynparza.com for more info]

Special Note

[uses, dosing may vary]

Info: refer to institution protocols and pkg insert prior to prescribing for uses and dosing incl. toxicity-related dose adjustments

ovarian CA, maintenance tx

[advanced BRCA-mutated dz, first-line tx]

Dose: 300 mg PO bid x2y; Info: for platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal CA; do not cut/crush/chew tab; may cont. beyond 2y if dz present and benefit outweighs risk

[advanced homologous recombination deficiency-positive dz, first-line tx]

Dose: 300 mg PO bid x2y; Info: for platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal CA; use w/ bevacizumab; do not cut/crush/chew tab; may cont. beyond 2y if dz present and benefit outweighs risk

[BRCA-mutated dz, recurrent]

Dose: 300 mg PO bid; Info: for platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal CA; do not cut/crush/chew tab

gBRCA-mutated HER2-negative breast CA

[high-risk early dz, adjuvant tx]

Dose: 300 mg PO bid x1y; Info: do not cut/crush/chew tab

[metastatic, previously treated dz]

Dose: 300 mg PO bid; Info: do not cut/crush/chew tab

metastatic gBRCA-mutated pancreatic CA, first-line maintenance tx

[300 mg PO bid]

Info: for pts without dz progression for at least 16wk after first-line platinum-based tx; do not cut/crush/chew tab

prostate CA, metastatic castration-resistant

[homologous recombination repair-mutated dz]

Dose: 300 mg PO bid; Info: for pts w/ progressive dz following enzalutamide or abiraterone; use w/ GnRH analog in pts w/o bilateral orchiectomy; do not cut/crush/chew tab

[BRCA-mutated dz]

Dose: 300 mg PO bid; Info: use w/ abiraterone; use w/ GnRH analog in pts w/o bilateral orchiectomy; do not cut/crush/chew tab

gBRCA-mutated ovarian CA, advanced

[indication withdrawn in US]

Info: mfr has voluntarily withdrawn this indication in pts who have received 3 or more lines of chemo d/t potential survival detriment

renal dosing

[adjust dose amount]

CrCl 31-50: 200 mg bid; CrCl <30: not defined

HD/PD: not defined

hepatic dosing

[see below]

Child-Pugh Class A or B: no adjustment; Child-Pugh Class C: not defined

Peds Dosing .

Peds dosing is currently unavailable or not applicable for this drug.